# Mark Vishnepolsky, M.D. – FDA 483, Jun 9, 2026

Source: https://www.keypedia.com/records/483/mark-vishnepolsky-md/eb2b817b-882d-4417-ac73-26d360f8ec94

> FDA 483 for Mark Vishnepolsky, M.D. on June 09, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Mark Vishnepolsky, M.D.
- Inspection Date: 2026-06-09
- Product Type: drugs
- Office Name: San Francisco District Office
- Summary: An FDA inspection of Mark Vishnepolsky, M.D. in Las Vegas, NV, revealed significant deficiencies in clinical investigation practices. The firm failed to adhere to the investigational plan by enrolling ineligible subjects and did not promptly report serious adverse events to the sponsor. Additionally, inadequate and inaccurate case histories were maintained, indicating a systemic lack of proper documentation and oversight in the clinical trial.

## Related Officers

- [Andra Lepnis](https://www.keypedia.com/people/andra-lepnis/38811302-3d96-427a-955d-c4c42de05a7c)
- [Lan T. Tran](https://www.keypedia.com/people/lan-t-tran/ab9c1008-c03f-425f-ac3c-a569d3e5037c)

Company: https://www.keypedia.com/companies/mark-vishnepolsky-md/50389205-3983-42ba-a53d-031fed73f0da

Office: https://www.keypedia.com/offices/san-francisco-district-office/6f838e9c-aae1-4665-9c46-a51d43be02df